Crossmark

In-situ Nanolipoidal Gel of Stiripentol for Intranasal Administration: Preclinical Evidence of Enhanced Biopharmaceutical and Therapeutic Outcomes

Crossref DOI link: https://doi.org/10.1208/s12249-025-03209-1

Published Online: 2025-08-25

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Mahajan, Harshada https://orcid.org/0000-0003-3856-6627
Nirbhavane, Pradip https://orcid.org/0009-0005-9974-4898
Chalikwar, Shailesh https://orcid.org/0000-0003-1550-1310
Moravkar, Kailas K https://orcid.org/0000-0002-0269-1576
License Information

Text and Data Mining valid from 2025-08-25

Version of Record valid from 2025-08-25
More Information

Article History

Received: 7 May 2025

Accepted: 24 July 2025

First Online: 25 August 2025

Declarations

:

: The authors declare no competing interests.